On September 23, 2026 Cartherics reported at two leading cell therapy conferences in Boston, sharing insights into the development and manufacture of scalable, off-the-shelf CAR-NK therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the 6th Annual iPSC Summit, Cartherics’ Head of Clinical Manufacturing, Dr Damien Zanker, presented ‘Manufacturing iPSC Therapies at Scale: Advancing Off-the-Shelf CAR-NK Production’ on 10 September.

The presentation highlighted Cartherics’ approach to building a scalable, consistent and secure iPSC manufacturing platform designed to support reliable CAR-iNK production. By engineering cells at the iPSC stage and establishing fully-characterised master cell banks, we create the starting point for a well-controlled differentiation process, providing the basis for enhanced product consistency and scalability – key attributes for developing off-the-shelf cell therapies.

Dr Zanker also presented at the 11th Annual CAR-TCR Summit on 17 September, with a presentation titled ‘Building Quality into iPSCs Early to Minimize Testing, Improve Reproducibility & Accelerate Commercialization.’

The presentation discussed how genetic engineering and quality considerations can be incorporated early in iPSC development to reduce downstream testing, improve reproducibility and support more efficient manufacturing.

Together, the presentations highlighted the important role of manufacturing in advancing iPSC-based cell therapies from research and development towards clinical application.

Cartherics is applying this manufacturing-led approach to its pipeline, including CTH-401, an iPSC-derived TAG-72 CAR-iNK therapy for relapsed/refractory ovarian cancer, which is progressing through IND-enabling activities ahead of first-in-human studies.

Cartherics was pleased to contribute its experience and perspective to discussions with the global iPSC and cell therapy communities in Boston.

(Press release, Cartherics, SEP 23, 2026, View Source [SID1234671021])